Financial Data and Key Metrics Changes - Elevance Health reported third quarter GAAP diluted earnings per share of $5.32 and adjusted diluted earnings per share of $6.30, reflecting enhanced medical cost management and expense discipline [17][19] - Total operating revenue for the quarter was $50.1 billion, up 12% year over year, driven by higher premium yields and growth in Medicare Advantage membership [19][20] - The consolidated benefit expense ratio was 91.3%, aligned with expectations [19][20] Business Line Data and Key Metrics Changes - Medicaid performance faced pressure from elevated acuity and utilization, with expectations of a modestly negative operating margin for the full year 2025 and a decline of at least 125 basis points in 2026 [20][24] - Medicare Advantage costs were marginally better than expected, with an anticipated slight increase in operating margin for 2025 [20][21] - The ACA market showed favorable development compared to expectations, but cost trends remain significantly above historical levels [21] Market Data and Key Metrics Changes - The company ended the quarter with 45.4 million medical members, with Medicaid membership concentrated among lower acuity members due to stringent eligibility reviews [19][20] - In the ACA market, the anticipated expiration of enhanced subsidies could significantly impact membership in 2026 [10][21] Company Strategy and Development Direction - The company is focused on lowering the total cost of care and improving member experience through an integrated clinical and benefits approach [5][6] - Elevance Health is committed to disciplined capital allocation, balancing investment in growth with consistent shareholder returns, and prioritizing returning capital to shareholders through share repurchases [15][23] - The company is investing in technology adoption, Careline capabilities, and operational initiatives to enhance performance and member satisfaction [42][44] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by rising medical and pharmacy costs and regulatory changes impacting coverage for millions of Americans [5][6] - The company is approaching 2026 with a prudent and practical posture, setting expectations that reflect current realities and uncertainties [6][14] - Management expressed confidence in the strategy and execution, anticipating a return to a more balanced earnings growth profile in 2027 [27][86] Other Important Information - The company is expanding external relationships and scaling pharmacy, behavioral health, and specialty care management, with external revenue growing double digits year over year [11][12] - The company is embedding AI-enabled tools to enhance access, efficiency, and engagement across its platform [13][44] Q&A Session Summary Question: Medicaid margin expectations and state discussions - Analyst inquired about the Medicaid margin outlook and the company's discussions with states regarding rate updates and cost trends [29] - Management clarified that the Medicaid trend assumption is anchored to expected fourth quarter exit rates, with elevated acuity and utilization driving pressures [32][33] Question: Investment spending and its impact on earnings - Analyst asked about the nature of investment spending and its potential transitory impact on earnings growth [40] - Management indicated that investments are focused on technology adoption, Careline scaling, and operational improvements, aimed at long-term growth [42][44] Question: Impact of enhanced subsidies on ACA membership - Analyst sought clarity on the potential impact of enhanced subsidies expiration on ACA membership [50] - Management acknowledged that expiration could lead to a material contraction in the ACA marketplace, with expectations of lower enrollments and higher morbidity risk [55] Question: Medicaid risk pool shifts and coding trends - Analyst inquired about the expected risk pool shifts and updates on coding trends from providers [101] - Management noted that elevated acuity and utilization pressures have not been fully offset by rate updates, and they are working on improving coding accuracy and compliance [104][106] Question: State partners' potential benefit adjustments - Analyst asked if state partners are considering pulling back on benefits to improve affordability [110] - Management confirmed that states are exploring various levers, including program changes, to enhance affordability in Medicaid programs [112]

Core Insights - Elevance Health reported a third quarter net income of nearly $1.2 billion, reflecting a 17.8% increase from $1 billion in the same period last year [4][3] - Total revenues for the third quarter rose by 12.4% to $50.7 billion, driven by higher premium yields and growth in Medicare Advantage membership [4][7] Financial Performance - The benefit expense ratio increased to 91.3%, up 180 basis points year over year, primarily due to elevated costs in the Medicare business [5] - Operating revenue for the third quarter was up 12% to $50.1 billion, influenced by recent acquisitions and growth in health benefits segments [7] Membership and Services - Elevance ended the third quarter with 45.4 million health plan members, a slight decrease of less than 1% compared to the previous year, attributed to lower BlueCard and Medicaid membership [7] - The Carelon health services business experienced significant growth, with operating revenue increasing by 33% to $18.3 billion, supported by acquisitions and scaling of risk-based solutions [7] Strategic Focus - The company emphasized disciplined execution and a focus on affordability and member experience through value-based care partnerships and AI-enabled digital solutions [6]

Q3 2025 Financial Performance - Elevance Health's Q3 2025 operating revenue reached $50.1 billion, a 12.0% increase year-over-year, driven by higher premium yields, acquisitions, and Medicare Advantage growth, offset by Medicaid reverifications[4, 7] - The benefit expense ratio was 91.3%, aligning with expectations but reflecting elevated costs across business lines[3, 7] - Adjusted diluted EPS was $6.03, including approximately $1 of higher net investment income and tax benefit timing[3] - Operating cash flow was $1.1 billion, impacted by the BCBSA Provider Settlement Agreement payment[7] Health Benefits Segment - Health Benefits operating revenue increased by 10.4% to $42.2 billion, driven by higher premium yields, acquisitions, and Medicare Advantage growth, partially offset by Medicaid reverifications[4, 9, 10] - Adjusted operating margin for Health Benefits declined by 280 bps to 1.4%, due to higher medical costs and strategic investments[9, 10] - Health Benefits membership stood at 45.4 million, reflecting lower BlueCard membership and Medicaid reverifications, offset by Medicare Advantage growth[9, 10] Carelon Segment - Carelon's operating revenue grew by 32.9% to $18.3 billion, driven by its integrated platform and performance in Pharmacy and Services[4, 12] - Adjusted operating gain for Carelon was $0.8 billion, a decrease of 9.5%[12] - Carelon Services revenue increased by approximately 60%, supported by the CareBridge integration and expansion of risk-based and home-health capabilities[13] Strategic Outlook - Elevance Health reaffirmed its full-year adjusted diluted EPS guidance of approximately $30, including a benefit expense ratio of approximately 90.0% and approximately $3 of discrete, non-core items[3] - The company anticipates Medicaid operating margin to decline by at least 125 basis points year-over-year due to rate increases lagging acuity and utilization trends[3] - Approximately 55% of Medicare Advantage members are in 4-Star or higher contracts for payment year 2027, up from approximately 40%[3]

Elevance Health (ELV) came out with quarterly earnings of $6.03 per share, beating the Zacks Consensus Estimate of $4.98 per share. This compares to earnings of $8.37 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +21.08%. A quarter ago, it was expected that this health insurer would post earnings of $9.16 per share when it actually produced earnings of $8.84, delivering a surprise of -3.49%.Over the last four quarters, the c ...

Core Insights - Elevance Health exceeded Wall Street profit estimates for the third quarter, leading to a 3% increase in shares during premarket trading [1] - The company managed to control medical costs despite warnings from several insurers about elevated costs in government-backed plans due to increased healthcare demand [1][2] Financial Performance - Elevance reported a quarterly medical loss ratio of 91.3%, an increase from 89.5% in the same period last year, but better than analysts' expectations of 91.73% [4] - The company's quarterly adjusted profit per share was $6.03, surpassing estimates of $4.93 [5] - Carelon's operating revenue rose approximately 33% to $18.3 billion, driven by recent acquisitions in home health and pharmacy services [5] Strategic Outlook - CEO Gail Boudreaux emphasized the company's disciplined execution and management as they plan for 2026 [2] - Elevance reaffirmed its adjusted profit forecast for 2025 at about $30 per share and projected a medical loss ratio of 90% [5] - The company had previously indicated elevated medical costs in its individual plans and Medicaid plans, primarily due to its Medicare business [3]

Core Insights - Elevance Health reported an increase in profit for the third quarter, driven by a rise in revenue despite a decline in overall memberships [1] Financial Performance - The company experienced higher profits in the third quarter compared to previous periods [1] - Revenue increased, contributing positively to the overall financial results [1] Membership Trends - There was a noted slip in overall memberships, indicating a potential area of concern for future growth [1]

Core Insights - Elevance Health reported third-quarter profit that exceeded Wall Street estimates, indicating strong financial performance [1] Financial Performance - The company successfully managed to keep medical costs in check, contributing to its better-than-expected profit results [1]

Financial Performance - Operating revenue for Q3 2025 was $50.1 billion, an increase of 12.0% from Q3 2024[5] - Diluted EPS for Q3 2025 was $5.32, with adjusted diluted EPS at $6.03[5] - Total revenues for the three months ended September 30, 2025, increased by 12.4% to $50,711 million compared to $45,106 million in 2024[38] - Health Benefits operating revenue for the three months ended September 30, 2025, rose by 10.4% to $42,246 million from $38,278 million in 2024[46] - Carelon's operating revenue reached $18.3 billion in Q3 2025, a 33% increase compared to the prior year quarter[23] - Carelon Services segment reported a significant increase in operating revenue of 57.9%, reaching $7,324 million for the three months ended September 30, 2025[46] - Net income for the three months ended September 30, 2025, was $1,187 million, reflecting a 17.8% increase from $1,008 million in 2024[38] - Operating revenue for the nine months ended September 30, 2025, increased by 13.9% to $148,273 million, compared to $130,215 million in 2024[59] Expense and Margin Analysis - The benefit expense ratio increased to 91.3%, up 180 basis points year-over-year, primarily due to cost trends in the Medicare business[9] - The operating margin for the Health Benefits segment was 1.4%, down from 4.2% in the prior year[14] - Operating expenses as a percentage of total operating revenue decreased to 10.5% for the three months ended September 30, 2025, compared to 11.8% in 2024[38] - The company’s benefit expense as a percentage of premiums increased to 91.3% for the three months ended September 30, 2025, compared to 89.5% in 2024[38] - Adjusted operating expense ratio for the three months ended September 30, 2025, was 10.4%, an increase of 100 basis points compared to 9.4% in 2024[59] Shareholder Returns - The company returned $3.3 billion of capital to shareholders year-to-date[5] - Shareholders' earnings per diluted share increased by 22.0% to $5.32 for the three months ended September 30, 2025, from $4.36 in 2024[38] - Shareholders' net income for the three months ended September 30, 2025, was $1,189 million, representing a 17.0% increase compared to $1,016 million in 2024[56] - The company expects shareholders' earnings per diluted share for the full year 2025 to be approximately $24.70[59] Cash Flow and Assets - Operating cash flow was $4.2 billion year-to-date, a decrease of $0.9 billion year-over-year[11] - Cash and cash equivalents at the end of the period increased to $8,713 million from $7,866 million in 2024[42] - Total assets as of September 30, 2025, were $122,749 million, up from $116,889 million at the end of 2024[40] Risks and Uncertainties - The company emphasizes that forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from projections[63] - Key risks include trends in healthcare costs, reduced enrollment, and the impact of large-scale medical emergencies[63] - There are concerns regarding compliance with complex regulations related to Medicare and Medicaid programs, which could affect revenue[63] - The company faces competitive pressures and must adapt to changes in the industry to develop strategic growth opportunities[63] - Risks associated with mergers, acquisitions, and joint ventures are acknowledged, which could impact future performance[63] - The potential negative effects of substantial outstanding indebtedness and increased interest rates on financing costs are noted[63] - There are risks related to international operations and the ability to attract and retain employees in a competitive market[63] - The company warns of possible restrictions on dividend payments from subsidiaries and the need for adequate capital levels[63]

Core Insights - Elevance Health, Inc. (ELV) is scheduled to report its Q3 2025 results on October 21, 2025, with earnings estimated at $4.97 per share and revenues of $49.5 billion [1][6] Earnings Estimates - The earnings estimate for Q3 2025 has seen one upward revision and two downward revisions, indicating a year-over-year decline of 40.6% [2] - The revenue estimate for Q3 2025 suggests a year-over-year increase of 10.7% [2] - For the full year 2025, the revenue consensus is $197.36 billion, reflecting a 12.6% year-over-year rise, while the EPS consensus is $29.96, indicating a 9.3% year-over-year decrease [3] Earnings Performance - Elevance's earnings have beaten the consensus estimate in two of the last four quarters, with an average surprise of negative 2.3% [3] Earnings Prediction Model - The current Earnings ESP for Elevance is +3.36%, but it holds a Zacks Rank of 4 (Sell), making an earnings beat uncertain [4] Revenue Drivers - The consensus estimate for product revenues indicates a 7.7% growth from the previous year's $5.9 billion, while premiums are expected to increase by 11.5% year-over-year [5][6] Cost and Expense Outlook - Elevated costs and benefit expenses are anticipated to impact profit margins negatively, with total expenses expected to rise around 9% year-over-year in Q3 [9] - The benefit expense ratio is estimated at 91.6, higher than the previous year's 89.5 [9] Segment Performance - The Health Benefits segment's operating income is projected to decrease by 45.5% year-over-year, with declining Medicaid memberships affecting premium growth [10]

Core Viewpoint - The market anticipates Elevance Health (ELV) will report a year-over-year decline in earnings despite higher revenues for the quarter ending September 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - Elevance Health is expected to report quarterly earnings of $4.97 per share, reflecting a year-over-year decrease of 40.6%, while revenues are projected to reach $49.5 billion, an increase of 10.7% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has been revised 1.57% higher in the last 30 days, indicating a collective reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model shows a positive Earnings ESP of +3.36% for Elevance Health, suggesting analysts have recently become more optimistic about the company's earnings prospects [12]. Historical Performance - In the last reported quarter, Elevance Health was expected to post earnings of $9.16 per share but delivered $8.84, resulting in a surprise of -3.49%. Over the last four quarters, the company has beaten consensus EPS estimates twice [13][14]. Investment Considerations - Despite a positive Earnings ESP, Elevance Health carries a Zacks Rank of 4, making it challenging to predict an earnings beat conclusively [12]. Investors should consider other factors beyond earnings results when evaluating the stock [15][17].